Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Kalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPA
Professor
University of Florida College of Pharmacy

Joshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.
2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-312-H01-P
Initial release date: 11/3/2025
Expiration date: 11/3/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Jamie Pitlick, PharmD, BCPS, BC-ADM
Professor and Chair of Pharmacy Practice
Drake University College of Pharmacy and Health Sciences

Joshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders.
2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-311-H01-P
Initial release date: 10/27/2025
Expiration date: 10/27/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Zachary Cox, PharmD
Professor
Lipscomb University College of Pharmacy

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.
2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-299-H01-P
Initial release date: 10/20/2025
Expiration date: 10/20/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Diagnosis and prescribing are no longer on the margins for pharmacy practice, but explicitly called out in the ACPE Standards that guide pharmacy education. Once considered out of bounds for pharmacists, diagnostic reasoning is now central to preparing practice-ready graduates. This episode explores how preceptors can support learners in applying clinical decision-making frameworks, integrating shared decision-making, and navigating prescriptive authority across diverse practice settings—equipping the next generation of pharmacists for expanded patient care.

HOST
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

GUESTS
Jennifer Adams, PharmD, EdD
Associate Professor, Associate Dean for Academic Affairs
Idaho State University L.S. Skaggs College of Pharmacy

Rachel Allen
Associate Teaching Professor
University of Washington School of Pharmacy

Cherith Smith, PharmD
Clinical Assistant Professor and Director, Experiential Education
University of Montana – College of Health Skaggs School of Pharmacy

Kathy Schott, Jennifer Adams, Rachel Allen, and Cherith Smith have no relevant financial relationships with ineligible companies to disclose.

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE INFORMATION
Learning Objectives
At the end of this course, preceptors will be able to:
1. Describe key principles of diagnostic reasoning and prescribing within the context of pharmacy practice.
2. Identify evidence-based frameworks such as the One-Minute Preceptor and shared decision-making to support learner development in clinical settings.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-319-H99-P
Initial release date: 10/15/2025
Expiration date: 10/15/2028
Additional CPE details can be found here.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Follow CEimpact on Social Media:
LinkedIn
Instagram

As questions continue to surface about the potential link between prenatal acetaminophen use and autism spectrum disorder, pharmacists must be prepared to address patient concerns with confidence and clarity. This episode explores the current body of evidence, public health messaging, and practical strategies for counseling during pregnancy. Tune in to strengthen your knowledge and support safe, evidence-informed guidance for your patients.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
John Swegle, PharmD
Clinical Associate Professor
University of Iowa College of Pharmacy

Joshua Davis Kinsey and John Swegle have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize current evidence regarding the association between prenatal acetaminophen exposure and autism spectrum disorder.
2. Identify patient counseling considerations for the safe use of acetaminophen during pregnancy.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-310-H01-P
Initial release date: 10/13/2025
Expiration date: 10/13/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Allergic reactions can range from a bothersome nuisance to a life-threatening emergency, making it crucial for pharmacists to stay informed about current treatment options and best practices. This episode discusses common triggers, effective therapies—from antihistamines and injections to the newly approved epinephrine nasal spray—and key counseling strategies to ensure patients receive safe, prompt relief. Tune in to improve your preparedness and support confident, patient-centered care.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

Rachel Maynard, PharmD
Lead Editor
Pyrls

Joshua Davis Kinsey and Rachel Maynard have no relevant financial relationships to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify common triggers and clinical features associated with allergic reactions.
2. Describe available treatment options for allergic reactions, including newly approved therapies and their appropriate use.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-300-H01-P
Initial release date: 10/6/2025
Expiration date: 10/6/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

With numerous new medications launching each year, pharmacists play a vital role in translating complex drug information into practical, patient-centered care. This episode offers a brief overview of select FDA-approved drugs from the past year, highlighting their therapeutic importance, key considerations, and clinical uses. Whether counseling patients or working with healthcare providers, pharmacists need to stay informed about what’s new—and understand its impact on practice.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Joe Strain, PharmD
Professor of Pharmacy Practice
South Dakota State University/Monument Health Rapid City Hospital

Joshua Davis Kinsey and Joe Strain have no relevant financial relationships to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. List unique pharmacological properties for select newly approved medications.
2. Recognize important safety considerations, including adverse effects, interactions, and monitoring parameters, for each featured drug.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-295-H01-P
Initial release date: 9/29/2025
Expiration date: 9/29/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The FDA remains a powerful driver of change in pharmacy practice through its approvals, policies, and public health actions. This episode highlights timely FDA developments and emerging areas of focus that pharmacists need to be aware of—from regulatory shifts to new communication initiatives. Tune in to stay informed on FDA activity that could influence the way you practice and care for patients.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Mary Ross Southworth, PharmD
Principal
S&S Consulting Partners

Joshua Davis Kinsey has no relevant financial relationships to disclose.
Mary Ross Southworth is a consultant for Travere, Unicycive, Liquidia, and Mineralys. All relevant financial relationships have been mitigated.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Recognize current FDA topics and areas of focus relevant to pharmacy practice.
2. Describe how current FDA priorities may impact medication use, pharmacist responsibilities, or patient care.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-296-H03-P
Initial release date: 9/22/2025
Expiration date: 9/22/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram